Physician profile
John N Green
NPI 1114072444
$900.10
in general payments reported to CMS, 2019-2025
17 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.50 · 2020: $25.88 · 2021: $277 · 2022: $62.18 · 2023: $144 · 2024: $151 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $238.55 | 2020-2024 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $138.22 | 2023-2025 | Arexvy, Shingrix |
| Bioventus LLC | $84.06 | 2024-2025 | Gelsyn-3, Durolane |
| Genentech USA, INC. | $82.58 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $60.91 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Abbott Laboratories | $47.50 | 2025 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $44.92 | 2021 | |
| Lilly USA, LLC | $31.21 | 2021-2023 | Mounjaro |
| Amgen INC. | $29.64 | 2023-2024 | Otezla, Repatha |
| Gilead Sciences, INC. | $25.00 | 2019-2021 | |
| Olympus America INC. | $18.22 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.07 | 2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $17.54 | 2023 | |
| Pfizer INC. | $17.00 | 2023 | |
| Vbi Vaccine (Delaware) INC. | $16.98 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15.38 | 2025 | |
| Corcept Therapeutics | $14.32 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.